Insights On Drug Discovery

1. Patient-Centric Formulations In Pediatric Adherence 11/13/2025

   Improving pediatric adherence requires age-appropriate formulations, taste-masking, and swallowability strategies. Regulatory, clinical, and technological insights help overcome barriers and support safer, more effective therapies for children across developmental stages.

2. Scientific Poster: Driving High-Titer Productivity And Faster Timelines 11/13/2025

   Accelerated cell line development delivers high-titer biologics in weeks, supporting diverse modalities with robust analytics, scalable productivity, and proven stability across 60+ generations.

3. Top 5 Cell Line Development Challenges (And How To Avoid Them) 11/6/2025

   The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

4. Optimize Your CLD With Innovative And Flexible Transposase Technology 11/6/2025

   To ensure speed and stability in the manufacture of your complex biologic — mAbs, antibodies, fusion proteins, and/or antibody drug conjugates — prioritize a high-performance CLD workflow.

5. Achieve Speed, Stability, And Compliance In Cell Line Development 11/6/2025

   Partnering with a CDMO that demonstrates innovative and commercially validated cell line development capabilities is essential to protecting your market position and securing investor support.

6. Smart Input Selection And Process Refinement For iPBMCs 11/5/2025

   Improved iPBMC manufacturing boosts TIL therapy reliability, safety, and affordability through donor screening, process refinements, and performance-based cell selection.

7. Top 8 Considerations For Choosing A PDX Model 10/7/2025

   To guide your decision-making, we’ve outlined the top 10 criteria to consider when evaluating PDX models for your next oncology research or drug development program.

8. Second Sourcing Is Natural ... Your Current CDMO Should Understand 9/23/2025

   Seasoned supply chain professionals say it is only natural to de-risk supply chains with sourcing materials and products at more than one external manufacturer ... no matter the insistence from the first external partner.

9. Preclinical Technique To Assess Targeted Therapies For Primary, Metastatic NSCLC 9/13/2025

   To enable comprehensive evaluation of therapies targeting both primary and metastatic tumors, we've developed dual-disease xenograft models using bioluminescence imaging (BLI).

10. Unlock The 3 Keys To Drug Discovery Success — Foresight, Hindsight, And Insight 9/13/2025

    If you don’t know where you are going, how will you get there? Articulating the destination of your therapeutic is essential for determining whether it is commercially viable and meets required milestones.